Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201603-08 Development of c-Met specific anticancer drug based on companion diagnostics (CDx) for the treatment of gastric cancer(Oncology, Chemical) [09.02.2016]

PRINT

Development and Market Objectives

The final goal of the project is to develop Best-in-Class c-Met inhibitor for personalized medicine with ABN401 small molecule.

Unmet Medical Need & Target Patients

Unmet Medical Need:

  • - Low survival and high relapse

  • - 5Yr postoperative survival: 35%
      Survival with chemotherapy: 40%

  • - Local regional relapse: 87%
      Remote metastasis: 30%

  • - Hard to apply standard therapeutics after relapse

  •  

Target Patients:

  • - Gastric Cancer patients

Status

- In vitro experiment to verify Mode of action

- Efficacy test compared to reference drug with Xenograft Model using gastric cancer cell line

- Efficacy test with Patient-Derived Xenograft (PDX) Model

Intellectual Property

- PCT application: Korea, China, Europe, Japan, India and USA

- Registration of patents are submitted

- New patents are under preparation

Competitive Advantages

- Currently, there is no FDA approved drug for the c-Met target.

- ABN 401 can be used as personalized treatment by c-Met specific inhibitor.

Indication

Oncology

Research Period

2016.8.1-2017.9.30

Company

ABION. INC

Developmental Stage

Optimization

Additional Information

Contact Information

Contact
Address Company Name: ABION. INC
WebSite Homepage: http://www.abionbio.com Contact Person: Eun Jin Kim
E-mail: ejkim@abionbio.com Contact: +82-2-6006-7615

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code